| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Graduate School of Neurosciences Amsterdam (Dr. Wolters and P.L.M. Bergmans), Department of Neurology, Free University Hospital, Amsterdam; Medisch Spectrum Twente (Dr. Jansen), Enschede; and Eli Lilly Nederland BV (Dr. Tuynman-Qua), The Netherlands.
Received December 27, 1996. Accepted in final form April 18, 1996.
Address correspondence and reprint requests to Dr. E.Ch. Wolters, Academisch Ziekenhuis Vrije Universiteit, Afdeling Neurologie, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
We studied the effect of olanzapine (1 to 15 mg/d) in 15 nondemented parkinsonian patients with drug-induced psychosis. Psychotic symptoms decreased significantly during treatment, and there was no worsening of extrapyramidal symptoms. These results suggest that olanzapine is a well-tolerated and effective treatment for drug-induced psychosis in nondemented patients with Parkinson's disease.
NEUROLOGY 1996;47: 1085-1087
This article has been cited by other articles:
|
|
 |
|
  U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Turjanski and G. G. Lloyd Psychiatric side-effects of medications: recent developments Adv. Psychiatr. Treat., January 1, 2005; 11(1): 58 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]
|
|
|
|
 |
|
 M. S. Ismail and I. H. Richard A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease? J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B R Thanvi, S K Munshi, N Vijaykumar, and T C N Lo Neuropsychiatric non-motor aspects of Parkinson's disease Postgrad. Med. J., October 1, 2003; 79(936): 561 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Hensiek and M R Trimble Relevance of new psychotropic drugs for the neurologist J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 281 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
H A Ring and J Serra-Mestres Neuropsychiatry of the basal ganglia J. Neurol. Neurosurg. Psychiatry, January 1, 2002; 72(1): 12 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marsh, C. Lyketsos, and S. G. Reich Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia Psychosomatics, December 1, 2001; 42(6): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Sa, A. E. Lang, S. Leucht, and C. Goetz Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, August 28, 2001; 57(4): 747 - 747. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
|
|
A Münchau and K P Bhatia Pharmacological treatment of Parkinson's disease Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610. [Full Text]
|
|
|
|
|
|
I. H. Richard and J. Nutt Worsening of motor function in Parkinson's disease: A ""typical"" response to ""atypical"" antipsychotic medications Neurology, September 26, 2000; 55(6): 748 - 749. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, September 26, 2000; 55(6): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Manson, A. Schrag, and A. J. Lees Low-dose olanzapine for levodopa induced dyskinesias Neurology, September 26, 2000; 55(6): 795 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aarsland, J. P. Larsen, J. L. Cummings, and K. Laake Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease: A Community-Based Study Arch Neurol, May 1, 1999; 56(5): 595 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Parkinson Study Group Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease N. Engl. J. Med., March 11, 1999; 340(10): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Graham, J. D Sussman, K. S Ford, and H. J Sagar Olanzapine in the treatment of hallucinosis in idiopathic parkinson's disease: a cautionary note J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 774 - 777. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Friedman and B. R. Ott Should Risperidone Be Used in Parkinson's Disease? J Neuropsychiatry Clin Neurosci, November 1, 1998; 10(4): 473 - 474. [Full Text]
|
|
|
|
|
|
A. E. Lang and A. M. Lozano Parkinson's Disease- Second of Two Parts N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Parsa and B. Bastani Quetiapine (Seroquel) in the Treatment of Psychosis in Patients With Parkinson's Disease J Neuropsychiatry Clin Neurosci, May 1, 1998; 10(2): 216 - 219. [Abstract] [Full Text]
|
|
|
|
|
|
J. M Graham, R. A Grunewald, and H. J Sagar Hallucinosis in idiopathic Parkinson's disease J. Neurol. Neurosurg. Psychiatry, October 1, 1997; 63(4): 434 - 440. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
